Studies on anthelmintic activity of medicinal plants have received insufficient interest and attention from researchers despite the high incidence of helminth infections in the poorer communities of South Africa. There are only a few anthelmintic remedies available which are inadequate in terms of accessibility, affordability and probably efficacy. In this review, we reappraised the various anthelmintic studies on South African medicinal plants to highlight how much and/or how little is known. The rich botanical and medicinal plant knowledge in South Africa is an indication of the potential of discovering potent treatments against helminth diseases in both humans and livestock. A total of 115 plant species encompassing 43 families screened for their anthelmintic potential (mainly nematodes) are listed in the current review. Combretaceae and Fabaceae were the most commonly used families. Tetradenia riparia, Hypoxis colchicifolia, Apodytes dimiata and Leucosidea sericea are a few examples of the South African species that have demonstrated promising anthelmintic activity. Even though other species such as Dicerocaryum eriocarpum, Berchemia zeyheri and Acorus calamus are potent anthelmintics, caution must be exercised in administering these plant extracts because of their potential toxic effects. Besides the benefit of validating the efficacy of traditional medicines, compounds from South African medicinal plants could also provide a template for novel synthetic anthelmintics. However, the major bottleneck in exploring more South African medicinal plants for anthelmintic properties is probably the lack of a robust, rapid and reliable screening technique as well as adequate funding schemes. Perhaps, there could be more success stories via increased research outputs with the development and availability of high throughput screening methods for assessing the activity of these medicinal plants as well as their resultant bioactive compounds. In addition, accessibility of funds to acquire latest technology and motivate researchers will inevitably stimulate more studies geared toward alleviating the problems posed by helminth infections.
Introduction
On a global level, Brooker et al. (2004) recommended the need for national governments to encourage more research into traditional medicinal plants and emphasized the importance of developing good policies, regulations and trade standards. Along this line, the South African government has proposed the integration of traditional medicine into the national healthcare system. However, the absence of stringent regulation mechanisms and secrecy within traditional medicine remains major stumbling blocks (Gqaleni et al., 2007) . Jäger (2005) raised concern on the relatively limited research focusing on diseases such as diarrhea, schistosomiasis and other helminthiasis affecting the majority of the population who are the main users of traditional medicine. For instance, only a few research groups such as the Research Centre for Plant Growth and Development, University of KwaZulu-Natal and the Phytomedicine Programme, Department of Paraclinical Sciences, University of Pretoria, have been actively involved in anthelmintic research. Furthermore, the lack of regulation in the prescription and usages of traditional medicines as well as inadequate toxicological evidence on the safety of the medicinal plants remain a problem (Fennell et al., 2004; Verschaeve and Van Staden, 2008) . Most importantly, there needs to be a holistic approach for traditional medicine that creates avenues to channel scientific information back to traditional healers (Jäger, 2005) . Helminth infections of both humans and livestock are of considerable importance (Hoste and Torres-Acosta, 2011) . Anthelmintics dominate the animal pharmaceutical industry being sold in the largest volume and having a high value (see International Federation for Animal Health website: http://www. ifahsec.org). Anthelmintic research and development has thus demanded a very large share of the animal health pharmaceutical development effort and is probably the only area of such research where efforts and success in animal health exceed those in human health (McKellar and Jackson, 2004) .
In this review, we highlight the limited available scientific data on helminth diseases in both humans and livestock despite the significant problems associated with the infections. In addition, the various techniques and safety of the South African medicinal plants screened for their anthelmintic properties in recent years (up till January 2012) are assessed. The review is expected to serve as an impetus for more studies to explore the rich South African flora.
Helminth infections and associated problems
Helminth infections such as ascariasis, hookworm infection and schistosomiasis constitute the core 13 neglected tropical diseases (NTDs) affecting the world population (Hotez et al., 2007) . Majority of the NTDs are well-pronounced among impoverished populations living in marginalized regions (Hotez et al., 2009) . In most developing countries, helminth infections have remained a major health concern because factors that pre-dispose humans to these infections abound in these areas. These incapacitating diseases continue to inflict severe disability and often death. In terms of disability-adjusted life years (DALYs), Hotez et al. (2006) estimated the global burden of helminth infections to be 39 million life years which is comparable to tuberculosis (34.7 million DALYs) and malaria (46.5 million DALYs), the two major human infectious diseases associated with high mortality rates. As a result, helminthiases have generally become the indices of low levels of socio-economic status of the countries where the infections are prevalent (Hotez et al., 2009 ). Children, especially those less than five years old, have been identified as the most vulnerable group with high rates of helminth infection (Sinniah, 1984) .
The infecting helminth species, degree of infection and host age, determine the clinical symptoms of helminth infection (Wang et al., 2008) . A number of factors that determine the pathogenicity of helminth infections include: exposure and entry; adherence and replication; cell and tissue damage; disruption, invasion and inactivation of host defenses (Murray et al., 1998) . Researchers have also observed a decline in host immune status as a result of helminth infection thereby increasing the host susceptibility to other pathogens and secondary infections (Borkow and Bentwich, 2006; Brooker et al., 2004) . Increasing direct and indirect evidences has indicated that helminth infection create an opportunity for more rapid infection by the human immunodeficiency virus (HIV) as well as quicker progression to acquired immune-deficiency syndrome (AIDS) and tuberculosis. In addition, the efficacy of some vaccines against HIV may be impaired by chronic helminth infection (Elias et al., 2006; Fincham et al., 2003; Wolday et al., 2002) . Ironically, studies have indicated that ailments such as asthma, heart and Crohn's diseases could be suppressed by some groups of helminths (Elliott et al., 2007; Magen et al., 2005) . Consequently, it has been predicted that the concept of some helminths may change from that of a strict parasite -harmful to the host, to a mutualist -providing benefit to the host as governors of immune-mediated inflammation in the near future (Elliott et al., 2007) . Active research to support this theory is ongoing but it is outside the scope of this review.
Due to the asymptomatic nature of helminth diseases, they can remain undetected and children born in an endemic region may harbor the worms for the greater parts of their lives (WHO, 1987) . Majority of the helminths consume nutrients from their host, thereby causing or aggravating malnutrition which results in retarded growth and physical development. Consequently, symptoms like retarded cognitive development, iron deficiency anemia, abdominal pains and related health problems are characteristic features of most heavy helminth infections (Kirwan et al., 2009) . Generally, helminth infections are regarded as a global problem of medical, educational and economic significances because of the long term chronic inflammatory disorders and disabling effects when left untreated (Prichard et al., 2012; Stepek et al., 2006; Wang et al., 2008) .
Prevalence of helminth infections in South Africa
In South Africa, especially the rural areas, the prevalence rate of helminth infections is alarming because factors such as poor sanitation and malnutrition that pre-dispose humans to these infections abound. Although there is no official data on prevalence and intensity of helminth infections in the country as a whole (Fincham et al., 1996; Schutte et al., 1995) , incidence of high prevalence rate of intestinal nematode infection in Mpumalanga (Evans et al., 1987) , the Western Cape (Fincham et al., 1996) and KwaZulu-Natal (Appleton et al., 1999; Mabaso et al., 2004) have been reported. Of particular interest is KwaZulu-Natal, the third poorest province in South Africa, which has a high mortality and prevalence of HIV/AIDS (Hirschowitz and Orkin, 1997) . In KwaZulu-Natal, the transmission and epidemiology problems of helminth infections such as Ascaris lumbricoides and Trichuris trichiura have remained relatively high over a long period of time (Jinabhai et al., 2001 ) and children remain the most vulnerable group (Saathoff et al., 2004) .
As with helminth infection rates in humans (Mkhize-Kwitshana et al., 2011) , the absence of prevalence surveys in recent times makes it difficult to substantiate the postulated high incidence rate in South Africa (Kaplan and Vidyashankar, 2012) . As is common in the tropics, Haemonchus contortus and Trichostrongylus colubriformis remain the most common nematodes that hinder production of ruminants in South Africa (Horak and Ursula, 2004; Van Wyk et al., 1999) . Helminthiasis is often controlled with the use of chemotherapeutics; however, the development of resistance to most of the commercially available anthelmintics has become a severe problem globally (Hoste and Torres-Acosta, 2011) . In fact, the first case of anthelmintic resistance (against ivermectin) was reported in South Africa (Van Wyk et al., 1987) .
Limitations of existing treatment regimes

Available classes of anthelmintic drugs and their mode of action
The existing pharmacopeia for both human and livestock helminth infections is severely limited (Geary et al., 2010) . The control of helminth infections requires a multi-faceted approach due to the complex life cycles of the causative organisms as well as environmental influences (Hoste and Torres-Acosta, 2011; Whitfield, 1996) . Currently, the use of broad spectrum chemotherapy is required for multiple worm infection in humans (Booth et al., 1998) and livestock (Hoste and Torres-Acosta, 2011) . In addition, proper health education, good hygiene and improved sanitation are indispensable in alleviating the spread of the causative organisms (Fincham et al., 2003; Savioli et al., 1992; Stepek et al., 2006) .
Based on their chemical structure and mode of action, there are only four classes of anthelmintics. The Class 1 drugs, known as the benzimidazoles (e.g. albendazole and mebendazole) were introduced in 1961. These drugs bind to free beta-tubulin and inhibit its polymerization, thereby interfering with the microtubuledependent glucose uptake by the parasite (Rang et al., 2003) . Class 2 imidazothiazole drugs e.g. levamisole, were discovered in 1966 and act by stimulating the nicotinic acetylcholine receptors leading to the paralysis of the worms which are subsequently washed out of the intestine by peristalsis (Stepek et al., 2006) . The third class of drugs, generally referred to as macrocyclic lactones, were introduced in the early 1980s (Chabala et al., 1980) . The first of such drugs was ivermectin which interferes with GABA-mediated neurotransmission resulting in paralysis and death of the helminth. These drugs act by paralysis of bodywall muscles in nematodes (Behnke et al., 2008) . In 1997, moxidectin, an analogue of ivermectin, which is the most potent macrocyclic lactone, was developed due to incidences of resistance and ineffectiveness of ivermectin against some groups of helminths (Geary, 2005) . The limited potency and safety of the three classes necessitated the search for new anthelmintics (Whitfield, 1996) . Finally in 2009, Novartis launched Zolvix®, a new class of anthelmintic referred to as the amino-acetonitrile derivatives (AADs) after 28 years of intensive research (Kaminsky et al., 2008b) . The AADs interfere with a unique ACR-23 nicotinic acetylcholine receptor subunit leading to the paralysis of the worms. In addition, AADs are relatively safe as evident from their low toxicity to mammals after various tests (Ducray et al., 2008; Kaminsky et al., 2008a) . Further studies by researchers involve the possibility of the potential synergetic action of different drugs (Tritten et al., 2012a,c) . In view of the wide diversity of helminthiasis and scope of the current review, more details on available chemotherapeutics, especially against other group of helminths such as cestodes and trematodes are available elsewhere (Geary et al., 2010) .
Rationale for exploring alternative treatments
'Global worming' is evident in countries such as South Africa, United States, Brazil and New Zealand (Kaplan and Vidyashankar, Caenorhabditis elegans 1.00 Negative -Ames and VITOTOX® Reid et al., 2006) ; and positive -micronucleus test McGaw et al. 2012). Despite the efficacy and relative safety margins of the available chemotherapies, there is a growing concern about potential problems of acquired resistance as varying degrees of resistance in nematode populations in humans and livestock have been reported globally (Albonico et al., 2003; Jabbar et al., 2006) . As further emphasized by Kaplan and Vidyashankar (2012) , the 'inconvenient truth' is that the development of anthelmintic resistance will almost certainly eclipse the discovery of new classes of anthelmintics. In fact, recent studies have indicated that AADs are not active against relevant human STH such as Necator americanus, Ancylostoma ceylanicum and Trichuris muris . In addition, the problem of reinfection after chemotherapy (Kirwan et al., 2009) , adverse drug complications in certain groups of people such as hepatitis patients, pregnant and lactating women have been highlighted. For a long-time, the number of anthelmintic drug research projects in academic laboratories and pharmaceutical industries globally were limited (Geary et al., 1999a) . Although more effort has been recently geared toward the search for new anthelmintic, the quantity of work and outputs is relatively small compared to other diseases such as cancer, HIV and malaria. This is partially due to limited financial gains to the multi-national pharmaceutical companies as the majority of people who suffer from helminthiasis are the poor (Smout et al., 2010) . Researchers need to explore and validate novel solutions or to rediscover ancient knowledge for a more sustainable control of helminth diseases (Hoste and Torres-Acosta, 2011; Mrazek and Mossialos, 2003) . The need to devote more efforts toward the discovery of new anthelmintics of plant origin has been strongly advocated (Athanasiadou et al., 2007; Waller et al., 2001) . In fact, the importance of plants as one of the natural sources of drugs cannot be over-emphasized. An estimated 87% of the global medications used against cancer, microbial and parasitic infections are derived from natural products, particularly higher plants (Newman et al., 2003) . Since antiquity, humans have used plants against ailments such as coughs, colds and parasitic infections; probably based on trial and error (Gurib-Fakim, 2006). C. elegans n/a n/a
Negative -Ames and VITOTOX® ; micronucleus test and comet assay ; and positive -brine shrimp toxicity assay (McGaw et al., 2007) McGaw et al. 
a Plant part(s): Tb = tuber; Wd = wood; Wp = whole plant; Rm = rhizome; R = root; Rb = root bark; L = leaf; T = twig; Ap = aerial parts; Bk = bark; and C = corm. b Assay method(s): DBA = Developmental and behavioral assay; and CA = colorimetric assay. c Concentration (mg/ml): n/a = not active at highest concentration tested.
Potential anthelmintic medicinal plants
The use of plants and their extracts for the treatment of a variety of human and livestock gastro-intestinal parasites have been in existence for a long-time (Waller et al., 2001 ). Some of the earliest known medicinal anthelmintic plants include Carica papaya, Ficus species and Ananas comosus. Until recently, anti-parasitic activity of most medicinal plants was based on anecdotal evidence, but there is currently an increase in the number of scientific studies aiming to verify, validate, quantify and determine the safety of these plants (Athanasiadou et al., 2007) . Globally, scientists have intensified efforts in the exploration of anthelmintics from natural products (Dornetshuber et al., 2009; Koné et al., 2011; Kotze et al., 2009; Muthee et al., 2011) . On the positive side, anthelmintic compounds such as santonin and filicic acids were isolated from Artemisia maritime and Dryopterix filix-mas, respectively (Setzer and Vogler, 2006) .
Contributions from South African researchers
In South Africa, medicinal plants have been used in the treatment of parasitic diseases of both man and livestock for centuries. The practice is still prevalent due to cultural reasons as well as the relatively high cost and inaccessibility of the existing chemotherapeutics (Clark et al., 1997) . Evidence of the use of South African plants is well documented in the commonly-used literature (Hutchings et al., 1996; Watt and Breyer-Brandwijk, 1962) and researchers have investigated some of these South African plants for their anthelmintic efficacy (Table 1) . We highlight 43 plant families consisting of 115 plant species that have been investigated for their anthelmintic property. The families included Combretaceae (21), Fabaceae (14), Asteraceae (7), Apocynaceae (7), Verbenaceae (5), Euphorbiaceae (4) and Rubiaceae (4) which accounted for more than 50% of the tested species. Based on the findings from cited studies, about 57% of the tested plant species exhibited various degrees of anthelmintic activity (Table 1) . Based on the in vitro test systems, examples of South African plants with promising anthelmintic activity include extracts from Markhamia obtusifolia (Nchu et al., 2011 ), Tulbaghia violacea (McGaw et al., 2000 , Combretum molle (Ademola and Eloff, 2010) , Hypoxis colchicifolia (Aremu et al., 2010b) , Cassinopsis illicifolia, T. riparia, and Coddia rudis (Okem et al., 2012) . In addition, Aloe ferox, Leonotis leonurus and Elephantorrhiza elephantina (Maphosa and Masika, 2012) have been shown to be effective anthelmintic remedies under in vivo test systems.
Overall, the number of scientific reports in this field is small compared to antimicrobial investigations (Fig. 1) . In South Africa, the continued neglect of anthelmintic studies is well pronounced with 8-fold more antimicrobial papers compared to anthelmintic papers published in South African Journal of Botany (Fig. 1 ). Even though current data were not based on a fully exhaustive and critical search of the entire database, it gives the general trend. There is a need to stimulate more interest and studies in this aspect of ethnopharmacology (Mrazek and Mossialos, 2003 ; Torres-Acosta et al., 2012). Particularly as helminthiasis is a serious problem to humans as well as livestock production and the increasing risk of drug resistance remains potentially detrimental (Patten et al., 2011) . Despite the limited available studies, some pharmacological important compounds (e.g. butelinic and lupeol) exhibiting anthelmintic have been isolated from South African medicinal plants (Fig. 2) . These compounds are also known for their diverse biological activities (Gallo and Sarachine, 2009; Yogeeswari and Sriram, 2005) .
Anthelmintic activity assays and test-organisms
Helminths belong to a very large group of organisms that are evolutionary diverse in body structure, biology and parasitic mechanisms (Fennell et al., 2004; Geary and Thompson, 2001) . It is thus imperative to ask questions that may mar or make the investigation. For instance, which test organism will be employed? What type of test system is required -in vitro or in vivo? In addition, important factors such as plant extracting methods and the effect of environmental and seasonal variations on the plant chemical composition, must be taken into consideration when evaluating the potential of medicinal plants for parasite control (Athanasiadou et al., 2007; Katiki et al., 2011) . These critical questions must be answered based on the aims of the experiment, available equipment and financial resources. In vivo and in vitro bioassays, as well as a number of test organisms, have been employed to screen plants for anthelmintic activity (Table 1) . Both test systems and the varieties of organisms employed have various limitations (Jabbar et al., 2006) .
In vivo versus in vitro -benefits and drawbacks
As in the case with other pharmacological screening, it is paramount to always use the 'best practice' approaches to research into various disease states (Houghton et al., 2007) . Most preliminary screening investigations of plants for anthelmintic activity utilize in vitro bioassays (Simpkin and Coles, 1981) . As evident in Table 1 , the majority (approximately 96%) of the studies in the current review were performed using in vitro systems. Generally, the main advantages of using in vitro bioassays include the low cost involved and rapid turnover that allow for large-scale screening of plants, as well as the low quantity of extracts required (Githiori et al., 2006; Whitfield, 1996) . The weakness of in vitro tests is that researchers often extrapolate results from in vitro tests to claim in vivo activity and/ or efficacy without taking into account vital factors such as absorption and bioavailability. Ideally, in vitro bioassays should be followed by in vivo tests when validating the anthelmintic activity of medicinal plants (Athanasiadou et al., 2007) . However, it becomes relatively more expensive to screen plant extracts on a large scale using in vivo studies. As a result, many scientists are content with preliminary experiments culminating in the numerous papers based on in vitro screening (Table 1) . Perhaps, better collaboration among local and international researchers as well as more financial support from the government and pharmaceutical companies would lessen the financial burdens. Inevitably, this could stimulate the feasibility of either scaling-up herbal mixture screening or the clinical trial of isolated compounds.
Commonly used test organisms
Numerous test models such as the free-living nematodes (Caenorhabditis elegans, Rhabditis pseudoelongata), earthworm (Pheritima posthuma), ascarids (A. lumbricoides), rodent nematode (Heligmosomoides polygyrus), trematode (Schistosoma mansoni), cestode (Hymenolepis diminuta) and trichostronylid (H. contortus) have been used in different studies (Githiori et al., 2006) . As observed in this review (Table 1) however, C. elegans remains the most frequently used test organism. The organism has long been employed for anthelmintic screening with limited success especially, in terms of discovery of valuable new leads (Geary et al., 1999b) . Apparently, it is regarded as the most suitable test organism for preliminary high-throughput in vitro screening for compounds with broad spectrum nematocidal activity (Geary and Thompson, 2001) , being the best representative of a large phylum that contains several parasites (Bürglin et al., 1998) . C. elegans belongs to the Order Rhabditida, which is closely associated with the Order Strongylida that contains the important trichostrongyle nematode parasites of ruminants, including H. contortus and Trichostrongylus spp. Furthermore, the sensitivity of C. elegans to most commercial anthelmintic drugs as well as the ease of culture growth and maintenance contributes to its widespread use for anthelmintic screenings (Katiki et al., 2011; Simpkin and Coles, 1981) . H. contortus is also commonly used as it is known for causing serious problems in small ruminant production (Table 1) . Despite the substantial benefits derived from the use of C. elegans, a number of limitations remain apparent (Geary and Thompson, 2001) . There is no single test organism without limitations thus; two or more test organisms should be used for anthelmintic screening. Besides, anthelmintics with a broad spectrum efficacy are of more value and useful in the search for new compounds/drugs. For instance, AADs were tested and proved effective against a wide range of helminths such as C. elegans and H. contortus (Ducray et al., 2008; Kaminsky et al., 2008b) but ineffective against other STHs .
Reappraisal of assay methods
Scientific evaluation or standards comparing the efficacy of plant extracts to commercial anthelmintics, as well as determining the level of anthelmintic activity are limited. As a result, there is high experimental variability that has led to an increased visible conflict of results on anthelmintic activity by plant extracts (Athanasiadou et al., 2007) . The discovery of new anthelmintics relies to a certain extent on the availability of an effective, rapid screening assay to detect anthelmintic properties (Gnoula et al., 2007; Smout et al., 2010) . Since the 1980s, the importance of automated screening involving the use of a micromotility meter has been recognized (Bennett and Pax, 1986; Folz et al., 1987) . Despite the usefulness of the approach, the inherent limitations restrict its application to small scale studies (Das et al., 1988) .
Researchers have employed different assays such as the larval arrested morphology assay (LAMA), larval development assay (LDA), larval motility assay (LMA), egg hatch test (EHT), adult development test (ADT), motility and colorimetric assays (Jabbar et al., 2006; Kopp et al., 2008) to evaluate anthelmintic activity. These various tests/assays can be partially divided into two major categories: i) developmental and behavioral assays (DBA) and ii) colorimetric assays (CA). In DBA, these anthelmintic studies require measuring the survival and/or reproductive potential of the worms after incubating with the test extracts for a specific time. The efficacy of the tested extracts/compounds is often measured based on the worms' viability (reproduction responses) or mobility (behavior responses) after the incubation period (McGaw et al., 2000) . Basically, the worms are stimulated (if necessary) and classified as either alive or dead/paralyzed. The efficacy is reported based on the relative number of death and paralysis due to the extract/drug compared to the controls. However, DBA are generally subjective, often unreliable, time consuming and laborious (Abdulla et al., 2009; Von Samson-Himmelstjerna et al., 2009 ). In addition, it is always difficult to distinguish between the paralyzed and dead worms (Gnoula et al., 2007) . Thus, a visual, qualitative and quantitative worm viability assessment was developed (James and Davey, 2007) .
In the CA methods, the test organisms are incubated with extracts or conventional drugs for specific duration. Thereafter, the metabolic activity is utilized as the measure of the test organism viability after the addition of an indicator compound, e.g. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide-formazan (MTT-formazan). Gnoula et al. (2007) also described a similar method with the use of a different indicator, 5(6)-carboxyfluorescein diacetate (CFDA) which fluoresced dead worms. Generally, CA provides a simple method for viability testing in potential anthelmintic plant extracts against C. elegans with the advantage of rapid evaluation. Several South African medicinal plants were screened with a modified CA method (Aremu et al., 2010a; Okem et al., 2012) . The use of p-iodonitrotetrazolium chloride (INT) instead of MTT-formazan worked well due to the better stability of INT. However, the use of CA is strictly only useful for in vitro evaluation and seems to have some inherent limitations. For instance, the use of response to indicators is likely to lead to loss of some potential anthelmintic extracts and compounds with moderate activity.
Recently, the successful application of a novel cell monitoring device (xCELLigence, Roche Inc.) system for anthelmintic screening was demonstrated Smout et al., 2010) . The technique assessed the real-time anti-parasite efficacy of synthetic anthelmintics on eggs, larvae and adults in a fully automated, label-free manner. It is a simple and objective high-throughput assay for anthelmintics screening as well as enabling resistance diagnosis by real-time monitoring of parasite motility. The method is postulated to be valuable for the majority of helminth species and developmental stages where EHA or motility is used as a measure of worm viability. As recently demonstrated however, xCELLigence system may only be useful in the presence of adult hookworms (Tritten et al., 2012b) . Despite the shortcoming of xCELLigence system, the application of this cutting-edge technology may be an invaluable tool for exploring the rich South African botanicals. However, the high cost could possibly hinder the availability of this cutting-edge technology to researchers in developing countries.
Safety of medicinal plants used as anthelmintics
A series of detailed systematic tests are basic and stringent prerequisites before pharmaceutical companies release any anthelmintic drug into the market. Thus, information on the efficacy, mode of action, pharmacokinetic parameters and potential environmental side-effects as well as the direct and indirect toxicities of the drug is known. Conversely, similar information on plant extracts or herbal products are limited or non-existent (Hoste and Torres-Acosta, 2011) . The widely held accepted belief and assumption are that natural products are safe, based on their long-term usage by humans and livestock (Verschaeve and Van Staden, 2008) . Nevertheless, recent investigations have revealed that some plants do have mutagenic and perhaps toxic effects Barlow and Schlatter, 2010) . This raises concern about the potential mutagenic health hazards resulting from the long-term use of such medicinal plants. Even though medicinal plants have benefits such as low cost, availability and acceptability, their safety and toxicity need to be evaluated and documented (Hoste and Torres-Acosta, 2011; Street et al., 2008) . In order to distinguish a clearly toxic effect from pharmacological efficacy, it is appropriate to incorporate toxicity and/or mutagenic tests when screening medicinal plants. Due to diverse mechanisms responsible for toxic and mutagenic effects, the importance of choosing the most appropriate and relevant safety evaluation method cannot be overemphasized. Generally, the Ames test is recommended for initial screening for mutagenic potential due to its long history of usage as well as the proven high degree of reproducibility of results and sensitivity (Mortelmans and Zeiger, 2000) . The Ames test was successfully used to screen a wide range of South African medicinal plant extracts (Verschaeve and Van Staden, 2008) and commercial herbal mixtures (Ndhlala et al., 2010) . The inclusion of S9 metabolic activation has been based on evidence that some mutagenic plant extracts or compounds only exhibit their mutagenicity after undergoing activation and transformation by enzymatic and metabolic processes Reid et al., 2006) . Other commonly used safety evaluation methods include the micronucleus test, comet and brine shrimp assays with their inherent pros and cons. For example, the brine shrimp assay is a simple, inexpensive technique for detecting cytotoxic potentials; however, it remains ineffective when such compounds required metabolic activation to become toxic (McGaw et al., 2007) . It is recommended that in vitro safety evaluation should be followed by in vivo experiments for confirmatory results. Table 1 highlights the safety evaluation of common South African medicinal plants with anthelmintic potential. In addition to their promising anthelmintic activity, H. colchicifolia Taylor et al., 2003) and A. dimiata (Brackenbury et al., 1997) were shown to be safe whereas D. eriocarpum, B. zeyheri, Gnidia capitata (McGaw et al., 2007) , A. calamus (Padmaja et al., 2002) , Senna petersiana (Tshikalange et al., 2005) and Clerodendrum myricoides (Reid et al., 2006) are potentially unsafe due to their toxic or mutagenic inducing effects. Furthermore, in other plant species such as Acacia karoo , L. leonurus (Maphosa et al., 2008) and Clematis brachiata (Afolayan et al., 2009) , the toxicity has been demonstrated to be dependent on the concentration of the extracts. Unfortunately, limited scientific data exist on the safety of other species such as Acokanthera oppositifolia, Mondia whitei and Berkheya speciosa. Thus, caution must be exercised when administering these plant extracts as anthelmintic remedies for both humans and livestock.
Evaluation of the safety of South African plants used as anthelmintics
Concluding remarks and future perspectives
Helminth infections affect a large proportion of the population, especially those living in informal and rural settlements as well as their livestock. There is also a growing resistance to the available chemotherapeutics with frequent cases of reinfection occurring. As with any class of drugs used against infective pathogens, development of resistance to new AADs (latest class of anthelmintics) remains a major concern (Prichard and Geary, 2008) . Medicinal plants provide mixtures of many chemical compounds possessing multiple biological activities. In South Africa, the vast number of medicinal plants and the traditional medicinal system remains poorly explored for anthelmintics. Thus, appropriate screening and evaluation of more medicinal plants with evidence of anthelmintic activity would offer possible alternative remedies that are sustainable. Besides validating the use of traditional medicines by providing a homecare herbal remedy against helminth infection, it could also serve as a preliminary phase in discovering leads for new anthelmintics.
However, researchers have continued to neglect anthelmintic investigation compared to other pharmacological properties such as antimicrobial, anticancer and anti-HIV activities. In vitro screening is important in validating the traditional use of medicinal plants as well as for providing leads in the search for new active principles. It could be a means of rapidly screening for potential anthelmintic activity in medicinal plant extracts and providing evidence for the possible mechanism(s) of the active compound(s). More so, the number of isolated bioactive compounds demonstrating anthelmintic activity is low.
Majority of the researchers have used the simplistic in vitro assays. It is essential to remember that noteworthy pharmacological activity identified in in vitro test does not always directly confirm that a plant extract is an effective medicine, or a suitable candidate for drug development. In view of the differences between in vitro and in vivo environments, active extracts should be subjected to in vivo investigation with the use of different parasitic test organisms. It is high time that we step out of the comfort zone by advancing the preliminary studies to in vivo systems, and ultimately clinical trials. Based on the inadequacy of current screening methods, we need to critically review and improve them for better efficiency. Finally, attempts at the isolation and identification of bioactive compounds as well as toxicity testing to determine the safety of the medicinal plants should be pursued rigorously. We recommend more collaboration among researchers both locally and internationally, the South African government should also increase the funding and incentives for scientists focusing on neglected diseases affecting the poor. In addition, an increase in the number of quality studies focusing on South African plants used as anthelmintics would certainly contribute positively to this expanding ethnopharmacological field.
